TSI receives first ever exclusive CFDA licence to produce HMB in China

By Cheryl Tay

- Last updated on GMT

TSI has been authorised to both produce and sell HMB in China.
TSI has been authorised to both produce and sell HMB in China.

Related tags Nutrition

Health product manufacturer TSI Group has announced the approval of the first ever China Food and Drug Administration (CFDA) Manufacturing Licence for β-hydroxy β-methylbutyrate (HMB) production in China.

The exclusive licence was granted to TSI’s Jiangyin Pharmaceutical facility (a wholly owned TSI Group company) to produce HMB for use in Chinese food products.

In addition to the existing approved Chinese HMB markets in sports nutrition and medical foods, the CFDA also gave the green light to the group’s HMB for a wider variety of Novel Food categories, such as baked goods, beverages, candies, and chocolates.

These new approvals make TSI the sole HMB manufacturer in China authorised to domestically produce and sell HMB ingredients to the food and functional food sectors in the country, which is a main target market for the group’s international muscle health growth strategy.

HMB is a naturally produced substance in the human body that is also used as a dietary supplement, as well as an ingredient in certain medical food products. Its status as a key functional ingredient in nutritional foods meant for adult nutrition is also growing.

TSI Group President Larry Kolb said: “These recent regulatory approvals are significant milestones for all of us at TSI. The door is now wide open for us to deliver TSI’s world-class HMB products to one of the fastest growing markets in the world — China.

“We know HMB can make a difference in people’s daily lives, and are excited for the opportunity to positively impact muscle health for millions of Chinese consumers, from athletes of all kinds to ageing adults.”

Related topics Suppliers Markets

Related news

Follow us

Products

View more

Webinars